A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
A phase 3 trial of Durvalumab in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT03706690 by AstraZeneca, with 407 participants enrolled, started 2018-11-27 and due to reach its primary completion in 2024-06-23. Interventions recorded: Durvalumab. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Durvalumab, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Shares Durvalumab, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialSafety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Shares Durvalumab, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.